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Cu(II) ions are implicated in the pathogenesis of Alzheimer
disease by influencing the aggregation of the amyloid- (A)
peptide. Elucidating the underlyingCu(II)-inducedA aggrega-
tion is paramount for understanding the role of Cu(II) in the
pathology of Alzheimer disease. The aim of this study was to
characterize the qualitative and quantitative influence of Cu(II)
on the extracellular aggregationmechanismand aggregatemor-
phology of A1–40 using spectroscopic, microelectrophoretic,
mass spectrometric, and ultrastructural techniques. We found
that the Cu(II):A ratio in solution has a major influence on (i)
the aggregation kinetics/mechanism of A, because three dif-
ferent kinetic scenarios were observed depending on the
Cu(II):A ratio, (ii) the metal:peptide stoichiometry in the
aggregates,which increased to 1.4 at supra-equimolarCu(II):A
ratio; and (iii) the morphology of the aggregates, which shifted
from fibrillar to non-fibrillar at increasing Cu(II):A ratios.We
observeddynamicmorphological changes of the aggregates, and
that the formation of spherical aggregates appeared to be a com-
mon morphological end point independent on the Cu(II) con-
centration. Experiments with A1–42 were compatible with the
conclusions for A1–40 even though the low solubility of A1–42
precluded examination under the same conditions as for the
A1–40. ExperimentswithA1–16 andA1–28 showed that other
parts than the Cu(II)-binding His residues were important for
Cu(II)-induced A aggregation. Based on this study we propose
three mechanistic models for the Cu(II)-induced aggregation of
A1–40 depending on the Cu(II):A ratio, and identify key reac-
tion steps that may be feasible targets for preventing Cu(II)-
associated aggregation or toxicity in Alzheimer disease.
Extracellular cerebral plaques composed mainly of amyloid
-peptide (A) 1–40 and 1–42 fibrils are a histopathological
hallmark of Alzheimer disease (AD)3 (1, 2). These plaques con-
tain elevated levels of metals, in particular zinc and copper (3).
Also, it has been shown that these metal ions can promote the
aggregation of A in vitro (4, 5). This implies a key role of the
metal ions in the A-mediated pathology of AD (6), although
the subject is still under much debate (7, 8), and a role of amy-
loid-independent pathways in AD neurodegeneration have
recently been reviewed (9).
Specifically regarding the role of metal ions in the amyloid-
mediated pathology of AD, it is believed that Zn(II) acts as a
neuroprotector (10, 11), whereas Cu(II) is considered to medi-
ate neurotoxicity (12–14). The latter effect is thought to occur
through early stage soluble A and A-Cu oligomeric interme-
diates (15–18) thatmay be involved in the formation of reactive
oxygen species (6). It was discovered that Cu(II) may be
released postsynaptically at glutamatergic synapses in hip-
pocampus (19, 20), the site for initial A deposition in AD. This
provides an explanation for how Cu(II) can interact with A.
Seemingly in contrast to the support for the neurotoxic effects
of Cu(II), recent evidence indicates a neuroprotective role of
intracellular Cu(I) via activation of intracellular neuroprotec-
tive cell signaling pathways that increase expression of A-de-
grading proteinases (21). In all events elucidating the underly-
ing molecular mechanisms of the A-Cu, interactions are vital
for understanding the role of Cu(II) in the pathology of AD, and
hence in developing new therapeutic strategies for the treat-
ment of AD (7, 22). Despite extensive studies, however, these
mechanisms remain largely unsettled and conflicting effects
have been reported; in some studies Cu(II) appears to be
involved in amyloid oligomerization (4, 23, 24), other studies
report that Cu(II) does enhance aggregation but only along
non-amyloidogenic pathways (17, 25), or even that Cu(II)
inhibits the aggregation of A (26). We recently showed that
Cu(II) could induce both oligomerization and non-oligomer-
ization pathways of A1–40 on the millisecond-second time
scale (27). Distinct oligomerization pathways have also been
reported for spontaneous oligomerization of A (28–30).
These reports show thatmultiple A oligomerization pathways
can co-exist, which could have major importance in under-
standing the molecular aspects of AD pathology. An intriguing
approach for elucidating the complex role of Cu(II) in the A
aggregation mechanism would be the use of complementary
kinetic methods as advocated in a recent review (31). In partic-
ular, kinetic studies on Cu(II) bound to A have been lacking,
and to our knowledge only end point determination of the cop-
per content in the amyloid aggregates has been performed (32,
33). Nevertheless, this information is as important as the out-
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come of studies on the peptide disappearance or aggregation
formation kinetics for elucidating the A-Cu(II) interplay and
will form the basis for studies of neuro-cytotoxicity under
defined metallopeptide conditions.
In this studywe investigated the influence of Cu(II) on aggre-
gation kinetics of A in vitro on the minutes-days time scale at
physiological conditions using a range of biophysical methods
in combination with simulations of the reaction kinetics. With
the objective of studying the underlying Cu(II)-induced A
aggregation mechanisms, we characterized the disappearance
kinetics of soluble species (including Cu(II)) as well as the for-
mation kinetics,morphology, ultrastructure, and stability of the
emerging fibrils and aggregates in solutions of A1–40, A1–42,
A1–28, and A1–16 using a combination of spectroscopic,
microelectrophoretic, mass spectrometric, and microscopic
techniques. We confirm concentration-dependent effects of
Cu(II) on the aggregation kinetics of A1–40 and A1–42. Most
importantly, we show for the first time that three different
aggregation scenarios exist depending on the Cu(II):A ratio,
and that Cu(II) co-aggregates with A. We directly show the
decrease in fibrillar structures concomitant with increases in
Cu(II) concentrations indicating a destabilizing effect of Cu(II)
on amyloid fibrils. Also, dynamic changes in the aggregatemor-
phology, where small, spherical aggregates appeared to be a
common end point were observed. Finally, we show that other
factors than the Cu(II)-binding His residues are of importance
in the Cu(II)-mediated aggregation of A. Based on the
obtained kinetic and morphological data, we propose three
mechanistic models for the Cu(II)-induced aggregation of
A1–40 depending on the metal:peptide ratio, and identify key
reaction steps that may be potential targets for preventing
Cu(II)-induced aggregation in AD. Also, whereas neurotoxicity
studieswere outside of the scope of the present studywe believe
that the results are important for conducting such studies
under well defined metal-ion conditions.
EXPERIMENTAL PROCEDURES
Peptide Preparation—Synthetic A peptides based on the
human sequences (A1–16, A1–28, A1–40, A1–42 95%
purity) were obtained from commercial sources (Bachem and
Caslo Laboratory). A marker peptide (PSKD) was purchased
from Schafer-N. All peptides were C-terminal carboxylic acids
and were purchased as lyophilized trifluoroacetate salts. The
sequence of each peptide is shown (Scheme 1).
A1–16, A1–28, and A1–40 were handled identically as
described below. A1–16/28/40 stock solutions were prepared by
dissolving 1 mg of lyophilized peptide in 1.5 ml of 20 mM
HEPES buffer (pH 7.40) containing 100 mM sodium chloride.
Tominimize the presence of both undissolved peptide and pre-
formed aggregates (34), the solution was sonicated for 5 min,
centrifuged at 14,000 g for 25 min at 5 °C, and finally filtered
(0.22 m filter). The peptide concentration was determined by
UV absorption spectroscopy using the molar extinction coeffi-
cient of tyrosine at 276 nm (  1,410 M1 cm1), and diluted
with the 20mMHEPES buffer to the appropriate concentration
(40 M unless stated otherwise) and immediately analyzed by
capillary electrophoresis or frozen and stored at 20 °C in
smaller aliquots. Prior to use, peptides were thawed at 5 °C, and
afterward kept on ice. The peptide solutionswere centrifuged at
14,000  g for 25 min (5) at 5 °C immediately after thawing to
remove aggregates formed during thawing. Then, 2/3 of the
upper supernatant was removed and mixed with an equal vol-
ume of 20 mM HEPES buffer without or with increasing con-
centrations of Cu(II). The concentration of A was confirmed
by reference to a standard curve using capillary electrophoresis
(CE). Differences with respect to kinetics or initial peptide con-
centration between samples that were used immediately upon
preparation and samples that had been frozen were not
observed at any point. The final concentration of Cu(II) in the
samples ranged between 0 and 200M. The 10mMCu(II) stock
solution was prepared from CuCl2. To prevent formation of
Cu(OH)2 4 molar eq of glycine were added to the stock solu-
tions (35).
A1–42 solutions were prepared by dissolving the lyophilized
peptide in high purity water and adjusting the pH to 10.5 with
NaOH. The samples were sonicated in ice water for 5 min and
centrifuged at 14,000  g for 25 min at 5 °C. The supernatant
was frozen in smaller aliquots and stored at 20 °C until use.
Due to themuch lower solubility ofA1–42 at neutral pH, all the
A1–42 experiments were performed at pH 10.5. Cu(II) solu-
tions used for experiments with A1–42 was prepared from
CuCl2 dissolved in high purity water.
Capillary Electrophoresis—CE experiments were performed
using a P/ACE MDQ CE instrument (Beckman Coulter). Elec-
trophoresis buffer was 20 mM HEPES (pH 7.4) containing 100
mM sodium chloride. UV detection was performed at   200
nm. Samples were incubated in the CE instrument at 37 °C. An
internalmarker peptide (PSKD)was added to theCE samples to
adjust for variation in injection volume and electroosmotic
flow. The concentration of soluble peptide was determined
from the corrected peak areas with reference to a standard
curve.
Thioflavin T (ThT) Fluorescence Spectroscopy—ThT fluores-
cence was measured using a FLUOstar Optima fluorescence
plate reader system (BMG Labtech). Equal volumes of peptide
and ThT solution with or without Cu(II) were mixed. The final
concentration of ThT was 20 M in all experiments. Sample
volume was 90 l of reaction mixture and the plates were incu-
bated at 37 °C. Blank samples with HEPES buffer and 20 M
ThT alone were analyzed to correct for background fluores-
1                   10                    20                 30                    40
Human A 1-42
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
Human A 1-40
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
Human A 1-28
DAEFRHDSGYEVHHQKLVFFAEDVGSNK
Human A 1-16
DAEFRHDSGYEVHHQK
SCHEME 1.
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cence by subtraction. The plate was shaken for 3 s prior to each
measurement using 1-mm orbital shake.
Inductively Coupled Mass Spectrometry (ICP-MS)—ICP-MS
investigations of the peptide aggregates were performed using a
PE-SCIEXELAN6000 instrument (PerkinElmer Life Sciences).
The peptide-Cu(II) samples were incubated at 37 °C and after-
ward centrifuged at 14,000  g for 1 h. The supernatant was
removed and the precipitate was dissolved by addition of high-
purity concentrated HNO3. This solution was diluted with the
20mMHEPESbuffer prior to ICP-MSanalysis. The total copper
content in the re-dissolved aggregates was quantified with ref-
erence to a matrix-matched calibration curve. The concentra-
tion of Cu(II) in solution (free plus peptide-bound) was calcu-
lated by subtraction of the aggregate-bound Cu(II) from the
total amount of Cu(II).
Atomic ForceMicrocopy (AFM)—ForAFM investigations the
peptide and peptide-Cu(II) samples were incubated at 37 °C.
Aliquots of 20 l from the incubation solution were applied
onto polished silicon wafersmodified by amino-silane at differ-
ent times after incubation. The depositedmaterial was carefully
washed three times with 100 l of water, and subsequently
dried in a gentle stream of nitrogen. All images were obtained
with a PSIA XE 150 microscope (Park Systems Inc.) in true
non-contact mode. The resonance frequency was 300 kHz and
the force constant was 40 newton m1. For each treatment a
minimum of three locations were investigated.
Scanning Electron Microscopy (SEM)—Samples for SEM
were incubated at 37 °C and applied on a silica wafer using the
same procedure as in the AFM experiments. The wafers were
sputter-coatedwith a10-nm thin gold layer prior tomeasure-
ment tomake the surface electrically conducting. Samples were
examined in an Ultra55 scanning electron microscope (Carl
Zeiss). An acceleration voltage of 3.00 kV and a 2-mmworking
distance were used. For each treatment a minimum of four
locations were investigated.
Data Analysis and Model Comparison—Data analysis and
fitting were carried out using GrapPad Prism 5.0 (GrapPad
Software). Concentration-time (CE and ICP-MSdata) and fluo-
rescence-time profileswere fitted to four differentmodels (sup-
plemental Equations S1–S4).Model discriminationwas carried
out by visual comparison of the fits, the size of the SE of the
fitted parameters, and by evaluation of the corrected Akaike’s
information criterion (AICC) (36). Further details are provided
under supplemental Materials.
Numerical Simulations—Simulations of the suggested reac-
tion pathways in Fig. 5 were performed by numerical integra-
tion of the corresponding differential equations using KinTek
Explorer (37) (KinTek Corporation). Further details are pro-
vided under supplemental Materials.
RESULTS
Spontaneous AAggregation Kinetics—To study the effect of
Cu(II) on the aggregation of A1–40, a kinetic model was estab-
lished for the spontaneous aggregation of A1–40. This was
done using CE to monitor the disappearance of soluble peptide
(Fig. 1, A and B) and fluorescence spectroscopy to detect the
concomitant appearance of aggregating ThT fluorescent spe-
cies (Fig. 1C).
The peak representing soluble A1–40 was narrow and sym-
metrical in the CE analysis (Fig. 1A) demonstrating that the
analyte was homogenous with respect to the charge-to-size
ratio and thus most likely represents the peptide monomer.
After an initial lag time the solubleA1–40 population started to
decrease and had almost fully disappeared after15 h (Fig. 1).
A simple two-step autocatalytic model (nucleation followed by
autocatalytic aggregation, supplemental Equation S1), that
accounts well for published kinetic data in various studies
of amyloidogenic proteins (38), fitted the CE data points ade-
quately over a range of peptide concentrations (40–120 M)
(Fig. 1B, inset). The ThT data showed that the formation of
fibrils could be described using the same two-step autocatalytic
model with curves (Fig. 1C) that are mirror images of the CE
data (Fig. 1B), and with rate constants of the same order of
magnitude as the values estimated from the CE experiments
(Table 1) and those previously determined for A using this
model (38). Thus, the two-step autocatalytic model was con-
cluded to be a suitable model for the spontaneous aggregation
of A1–40. In addition to the CE and ThT experiments with
apo-A1–40, CE was used to follow the aggregation kinetics of
A1–42 at pH 10.5 (40 and 60 M, supplemental Fig. S1). The
spontaneous aggregation of A1–42 could also be described by
the two-step autocatalytic growth model (supplemental Fig. S2
and Table S1).
Cu(II) Affects the A Aggregation in a Concentration-depen-
dent Manner—Next, we studied the effect of Cu(II) on A
aggregation. There are conflicting reports on the Cu(II):A
binding stoichiometry (33, 39). Also, as noted by others (39), a
physiological relevance of supraequimolar Cu(II):A ratios is
possible, because the concentration ofA in CSF is in the nano-
molar range (40, 41), whereas the release of Cu(II) from neu-
rons may reach micromolar levels in the extracellular space
(19). Thus, three different Cu(II) concentrations (10, 40, and
200 M) were chosen to reflect subequimolar (0.25:1), equimo-
lar, and supra-equimolar (5:1) Cu(II):A ratios.
In the presence of Cu(II), aggregation of A1–40 started
instantaneously at all three Cu(II):A ratios (Fig. 1B). This is in
agreement with other studies (4, 5). The individual kinetic pro-
files, however, varied considerably depending on the molar
ratios. At subequimolar Cu(II):A ratios, the kinetic curves
were similar to the profile of the apo formwith the exception of
an initial decrease of about 10 M in soluble A1–40 as deter-
mined from the first CE measurement (3 min after start of
incubation, Fig. 1B, blue trace). This indicates that the added 10
M Cu(II) immediately (3 min) induced aggregation of an
equimolar amount of A1–40 upon addition. The remaining
soluble A1–40 followed the spontaneous aggregation pathway
(the two-step autocatalytic mechanism) as illustrated by both
the CE and ThT data (Fig. 1, B and C, and Table 1), indicating
that the presence of aggregated A-Cu did not influence the
self-assembly process of the remaining peptide in solution.
Note that the A1–40 aggregating instantly uponCu(II) incuba-
tion, as detected by CE, do not result in an increase in ThT
fluorescence, contrary to the subsequent aggregation of the apo
A1–40. Thus the initially formed aggregates with Cu(II) had
only minimal -sheet structure.
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At equimolar Cu(II):A ratios, the aggregation kinetics was
surprisingly found to be much slower and soluble peptide was
still detected after 70 h (Fig. 1B, purple triangles). After an
initial decrease of 5–15 M in the concentration of soluble
peptide (Fig. 1B and supplemental Fig. S3) the concentration of
soluble A1–40 slowly decreased linearly with time. Similar
kinetics was observed for the increase in ThT fluorescence (Fig.
1C, purple trace). The two-step autocatalytic model did not
adequately describe this data set, which was best fitted by a
linear function (supplemental Equation S2). This strongly sug-
gests that different aggregation mechanisms were involved
under subequimolar as compared with equimolar conditions.
We suggest the existence of a relatively stable and soluble
A-Cu complex as previously proposed (42), because of the
FIGURE 1.Aggregation of 40MA1–40 in 20mMHEPES (pH7.4) and 37 °C.A, electropherograms at various times after incubation showing the disappear-
ance of soluble A1–40 due to spontaneous fibrillation (apo) and Cu(II)-induced aggregation (holo). A marker peptide (M) was added to the solution. B, disap-
pearance kinetics of soluble A1–40 in the absence (F, black) and presence of 10 (f, blue), 40 (Œ, purple), and 200 (, red) M Cu(II). Data are fitted to
supplemental Equation S1 (0 and 10M), supplemental Equation S2 (40M), and supplemental Equation S4 (200M). Inset, effect of A1–40 concentration on
the spontaneous (i.e. in the absence of Cu(II)) fibrillation of the peptide. Initial A1–40 concentration is 40 (), 85 (ƒ), and 120M (F, black). Data were fitted to
a two-step autocatalytic mechanism (supplemental Equation S1). C, fibril formation kinetics of A1–40 from one ThT experiment in the absence (F, black) and
presence of 10 (f, blue), 40 (Œ, purple), and 200 M (, red) Cu(II). D, disappearance kinetics of soluble Cu(II) determined from ICP-MS. 40 M A1–40 was
incubated with 10 (f, blue), 40 (Œ, purple), and 200 M (, red) Cu(II). Data points are mean S.D. (n 3).
TABLE 1
Rate constants for the aggregation of A1–40 (40M) and added Cu(II) (10–200M), and formation of ThT-positive aggregates
The experiments were performed at 37 °C in 20mMHEPES buffer with 100mMNaCl (pH 7.4). Values are best-fitted values S.E. The range of the individual best fit is listed
in brackets for k1 in the two-phase autocatalytic (AC) model. n is the number of individual experiments. For the two-phase ACmodel k1 is the rate constant of nucleation,
and k2 is the rate constant of fibril growth. For the linear function model, k1 is the 0 order rate constant. For the bi-exponential model k1 is the rate constant for the fast
exponential term, and k2 is the rate constant for the slow exponential term. For more details see the supplemental materials.
Cu(II):A1–40 ratio Measured specie Model k1 k2
0 Aa Two-phase ACb (n 4)c (4.8 109–1.2 106) s1 (3.5 0.3) 106 M1 s1
0 Aggregatesd Two-phase ACb (n 3)c (1.0 109–3.8 105) s1 (6.15 0.05) 106 M1 s1
0.25 Aa Two-phase ACb (n 3)c (2.7 108–9.0 107) s1 (2.8 0.2) 106 M1 s-1
0.25 Aggregatesd Two-phase ACb (n 3)c (7.7 108–1.1 106) s1 (2.75 0.03) 106 M1 s1
0.25 Coppere Linear functionf (n 3) n.s. (p 0.463)g
1 Aa Linear functionf (n 4)c (1.2 0.3) 104 M s1
1 Copperd Linear functionf (n 3) (6.8 0.7) 105 M s1
5 Aa Biexponentialh (n 3)c (3.3 0.2) 104 s1 (6.5 0.2) 106 s1
5 Aggregatesd Biexponentialh (n 3)c (5.8 0.5) 104 s1 (7.7 0.2) 105 s1
5 Coppere Biexponentialh (n 3) (4.3 2.0) 104 s1 (4.0 2.0) 106 s1
a Detected with CE.
b Supplemental Equation S1.
c Global fit.
d Detected with ThT fluorescence spectroscopy.
e Detected with ICP-MS.
f Supplemental Equation S2.
g Statistical test for significantly non-zero slope.
h Supplemental Equation S4.
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slow aggregation kinetics of A1–40 at equimolar Cu(II):A1–40
ratios. The aggregation of this soluble complex becomes the
rate-limiting step of the aggregation process.
At supraequimolar Cu(II):A1–40 ratios an initial fast
decrease in the soluble peptide was observed within the first 2 h
corresponding to 65% aggregation of the peptide (Fig. 1, A
andB, red diamonds, and supplemental Fig. S3). After the initial
fast phase the disappearance rate of soluble A1–40 decreased
and soluble peptide was still detected after 50 h (Fig. 1B). A
similar pattern was seen for the aggregate formation kinetics
measured by ThT fluorescence where an initial fast increase in
the fluorescence intensity was observed during the first 1–2 h
(Fig. 1C, red trace, and supplemental Fig. S3) followed by a
relatively constant and stable fluorescence signal over the next
40–50 h. The soluble A1–40 remaining after 50 h was not
susceptible to further Cu(II)-induced aggregation (supplemen-
tal Fig. S4). This indicates that the remaining soluble peptide
was already fully loadedwith Cu(II), and that the aggregation of
a soluble A-Cuy complex is rate-limiting as observed under
equimolar conditions. Recently it has been shown that Cu(II)
decreases the hydrophobic exposed protein surfaces of A1–40
when added in supraequimolar ratios (43), which may explain
the observed increased solubility of the A-Cu complex.
Both the peptide loss (CE data) and the aggregation forma-
tion kinetics (ThT data) at supraequimolar ratios were best fit-
ted to a sum of two exponential functions (supplemental Equa-
tion S4). However, upon closer comparison of the CE and ThT
profiles (Fig. 1, B and C, red traces) it was evident that there
were some differences with respect to the slower phase (Table
1). The slow loss of peptide seen after 3–4 h using CE did not
give rise to an increase in ThT fluorescence. This again suggests
that there were structural differences between the initially
formed aggregates and the aggregates slowly formed during the
second phase. The structural difference is most likely reflected
in the amount of -sheet present in the aggregates. Further-
more, the initial decrease in soluble peptide occurred in parallel
with the increase in ThT fluorescence. This suggests that the
aggregates formed initially within the first hours at suprae-
quimolar Cu(II):A ratios are structurally different from the
aggregates that were formed initially at the subequimolar ratio,
because an initial increase in ThT fluorescence were not
observed under these conditions, despite a decrease in soluble
peptide, see above (Fig. 1, B and C, blue traces).
Moreover, CE studies were performed to study the influence
of Cu(II) on the aggregation of A1–42 using the same metal:
peptide ratios. Like the case with A1–40, the Cu(II):A1–42
ratio also influenced the aggregation kinetics of Cu-A1–42 and
different kinetic scenarios were also observed depending on the
Cu(II):A1–42 ratio that all differed from the spontaneous
aggregation of A1–42 (supplemental Figs. S1 and S2, andTable
S1). It should be noted that the apparent aggregation kinetics of
Cu-A1–42 was not identical to the aggregation kinetics seen
for Cu-A1–40 at the samemetal:petide ratios. However, due to
the difference in experimental conditions (e.g. pH), a detailed
comparison of the kinetic profiles of A1–40 and A1–42 was
not possible. The qualitative observation that the Cu(II)-in-
duced aggregation kinetics and hence aggregation mechanism
was dependent on the metal:peptide ratio for both A1–40 and
A1–42 was consistent, however, and suggests that the propen-
sity to entermultiple aggregation pathways is an inherent prop-
erty of A peptides. In summary, both the CE and ThT exper-
iments showed that the rate of loss of soluble peptide and the
emergence of ThT-positive aggregates strongly depend on the
metal:peptide ratio, and that three different Cu(II)-induced
aggregation pathways exist depending on this ratio.
Cu(II) Binds to A Aggregates in Different Ratios—To exam-
ine the disappearance kinetics of soluble Cu(II), we used
ICP-MS to measure the copper content in isolated A-Cu
aggregates (Fig. 1D). At subequimolar Cu(II):A ratios all the
copper was bound in the aggregated material (cCu(II) in the
redissolved aggregates was 10 1M,mean S.D., n 12), i.e.
all Cu(II) had disappeared from solution at the first ICP-MS
measurement (1 h, Fig. 1D, blue squares). This confirms that
the 10 M A1–40 that instantaneously aggregates upon addi-
tion of 10 M Cu(II) in the CE experiments (Fig. 1B, blue
squares) contained copper in a 1:1 stoichiometry. This is com-
patible with the notion that A1–40 has one high affinity Cu(II)-
binding site (33, 39) and that Cu(II) is bound to the aggregates
in a 1:1 ratio (32, 44). In addition, ICP-MS data showed that the
copper stays bound to the aggregates during the entire time
course of the experiment (72 h).
At equimolar ratios, 26 M Cu(II) remained in solution
after the first measurement (Fig. 1D, purple triangles). This also
corresponds well with the observed initial decrease in soluble
peptide (Fig. 1B, purple triangles, and supplemental Fig. S3)
confirming the 1:1 stoichiometry of the A-Cu(II) aggregates.
Hereafter, the concentration of soluble Cu(II) decreased at a
constant rate that was comparable with the decrease in soluble
peptide (Table 1). This supports our previous notion that aggre-
gation of the soluble A-Cu(II) complex is a rate-limiting step,
see above, and shows that the complex retained its metal:pep-
tide stoichiometry upon aggregation.
At supra-equimolar ratios an initial fast decrease in the sol-
uble Cu(II) concentrationwas seen followed by a slower second
phase (Fig. 1D, red diamonds). This two-phase kinetics also
agrees with the kinetics seen in the CE and ThT experiments
(Table 1). This confirms that Cu(II) was bound to A1–40 upon
aggregation. The analysis of the peptide and Cu(II) aggregation
kinetics at the supra-equimolar concentration shows that cop-
per was bound to the A aggregates in a constant molar metal:
peptide ratio of 1.4 0.1 (mean S.D., n 15) throughout the
time course of the experiment. This implies that a second
Cu(II)-binding site is partially occupied in the A-Cu(II) aggre-
gates at this metal:peptide ratio, and this could be a reason for
the apparent structural differences in the aggregates as detected
by the ThT fluorescence. Conclusively, the ICP-MS data
showed that copper co-aggregates with A in a 1:1 stoichi-
ometry at Cu(II):A ratios 1 and in a 1.4 ratio at Cu(II):A
ratios1.
Cu(II) Promotes Time-dependent Changes in the Morphology
of Aggregates—The studies of peptide disappearance and aggre-
gate formation kinetics demonstrated that Cu(II) has a pro-
found influence on the aggregation kinetics of A1–40. Also,
from the ThT experiments it is evident that the fluorescence
signal itself is affected by the amount of Cu(II) present because
a decrease in the plateau intensity was seen with increasing
Cu(II)-dependent A Aggregation Pathways
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Cu(II) (Fig. 1C). A study on A1–42 reports that the ThT fluo-
rescence intensity after a 6-h incubation at 37 °C with 5 molar
eq of Cu(II) is reduced to about 20% of the intensity without
Cu(II) (26). This reduction is identical to our ThT results with
excessCu(II), where an 80% reduction in intensitywas observed
(Fig. 1C, red trace). However, contrary to the previous study
where it is concluded that the reduction in ThT signal is due to
Cu(II) inhibiting the aggregation of A1–42 (26), our CE results
clearly indicate that Cu(II) induced pronounced aggregation of
A in the first hours after incubation. Thus, the relative
decrease inThT fluorescence intensity in the presence of Cu(II)
most likely reflects a decrease in the number of ThT binding
sites (45), i.e. a decrease in the -sheet content of the peptide
aggregates as compared with the situation in the absence of
Cu(II) (46). Additionally, Cu(II)-dependent quenching also
takes place especially in the presence of excess Cu(II). The
above findings suggest Cu(II)-dependent differences in aggre-
gate structure. Earlier reports have suggested that the amy-
loidogenic characteristics of Cu(II)-treated fibrils is decreased
(15, 17).
The time-specific morphology of the fibrils and aggregates
was studied usingAFM (Fig. 2).WithoutCu(II), fibrils or aggre-
FIGURE 2. AFM pictures of the aggregates formed from 40 M A1–40 solution at different metal:peptide ratios and incubation times as indicated.
Fibrils were not detected initially in the absence of Cu(II) (A). Fibrils were observed in the absence of Cu(II) after 4 h (B). Spherical aggregates were observed on
top of fibrils after 24 and 72 h (C andD). Amorphous aggregates were observed in the presence of Cu(II) (E–P). The aggregates showed some fibrillar structure
(E and G). Fibrils were not detected at equimolar and supra-equimolar Cu(II) concentrations (I–P). The experimental conditions were the same as described in
the legend to Fig. 1.
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gates were not detected initially (Fig. 2A), which is in good
agreement with the observed kinetics where a lag phase of
3–10 h was observed (Fig. 1, B and C). This also verifies that
only minimal amounts of insoluble aggregated A are initially
present in the filtered and centrifuged peptide solutions. Small
fibrils were observed after 4 h (Fig. 2B). These fibrils continued
to grow in length and number until 24 h where they reached a
length of 2–3 m and a height of 10–20 nm (Fig. 2C). This
agrees with the observed kinetics, where all soluble peptide dis-
appeared (Fig. 1B) and a maximum ThT fluorescence was
observed after about 20 h (Fig. 1C). The fibrils were unbranched
but intertwined and in some cases appeared to have a common
nucleus from which multiple threads were sprouting (Fig. 2B,
inset). After prolonged incubation the number of fibrils
appeared to decrease (Fig. 2D). Instead, small spherical aggre-
gates were observed ranging from 10 to 100 nm in diameter
lying on top of the formed fibrils like pearls on a string. These
aggregates resemble previously reported early oligomeric
assemblies of A1–40 (47), andwere alsomorphologically indis-
tinguishable from the Cu(II)-induced aggregate species
observed in this study (see below) and elsewhere (15). However,
the presence of spherical assemblies subsequent to fibrillation
in the absence of metal ions has to our knowledge not previ-
ously been reported, although they have been observed prior to
fibril formation (48). Transformation of fibrils into spherical
aggregates over time is consistent with the observation that the
ThT fluorescence slowly decreases after having reached an ini-
tial plateau (data not shown).
At a 0.25:1 molar metal:peptide ratio amorphous aggregates
and a few fibrillar structures were seen immediately upon addi-
tion of Cu(II) (Fig. 2E). This corresponds well with the kinetics
observed in the CE analyses (Fig. 1B, black circles) where a
decrease in the concentration of soluble peptide was detected
immediately after incubation. Although the aggregates dis-
played some fibrillar characteristics (Fig. 2E, inset), they were
generally amorphous in nature (Fig. 2F). After 24 h, individual
fibrils were observed but amorphous aggregates still predomi-
nated (Fig. 2G). The formed aggregates had some amyloido-
genic properties because a relatively high signal was attained in
the ThT assay of these solutions. After 72 h fibrils were com-
pletely absent and only small spherical aggregates with a diam-
eter of40–60 nm were detected (Fig. 2H).
Incubation of A1–40 with equimolar and supra-equimolar
concentrations of Cu(II) led to immediate formation of large
amorphous aggregates without any apparent fibrillar morphol-
ogy as detected by AFM in accordance with earlier studies (15,
49, 50). At the 1:1 ratio the aggregates increased in size (from
about 100–400 nm to1 m) until 24 h of incubation (Fig. 2,
I–K). Afterward the aggregates diminished in size but increased
in numbers (Fig. 2L) in accord with the decrease in soluble
peptide seen in the CE experiments (Fig. 1B). Fibrils were not
detected by AFM at any time point at the 1:1 metal:peptide
ratio. However, the formed aggregates could have some amy-
loidogenic properties because a steady increase in the ThT sig-
nal was observed in parallel with the disappearance kinetics of
soluble peptide (Fig. 1, B and C). It should be noted that the
increase inThT intensity could be independent on the presence
of any form of fibrillar structures (51).
At the 5:1 metal:peptide ratio large aggregates were seen
immediately upon Cu(II) addition (Fig. 2M). The aggregates
were similar in size to the aggregates formed at the 1:1 ratio.
After4 h, aggregateswere seen possessing some fibrillar char-
acteristics (Fig. 2N, inset), and this could explain the rapid
increase in ThT fluorescence observed during the first 5–10 h
at this concentration level (Fig. 1C, red trace). At 24 and 72 h
only small spherical aggregates were found (Fig. 2, O and P)
resembling those seen at 72 h at 0.25:1 and 1:1 Cu(II):A ratios
(Fig. 2, H and L).
We also examined the incubated peptide solutions using
SEM, to gain complementary information about the aggregate
morphology (supplemental Fig. S5). Overall, the morphology
and evolution of fibrils and aggregates detected by SEM were
identical to what was observed with AFM. The only difference
was that in the SEM the Cu(II)-induced amorphous aggregates
still displayed a relatively high degree of fibril-like structure
with fibrils laterally aggregated in bundles. This is consistent
with previous studies using TEM (39, 52) and would also
explain the detection of an increase inThT fluorescence even in
the presence of Cu(II). The presence of this fibrillar structure
may not be so easily discerned on an aggregate background
using AFM.
In summary, AFM and SEM document distinct aggregate
morphologies depending on the Cu(II):peptide ratio and the
incubation time. The insoluble phase is strikingly dynamic
changing from fibrillar to a mixture of fibrillar and spherical
structures. Cu(II) consistently induced aggregates with minor
or no discernable fibrillar structure. Also, in all AFM experi-
ments small spherical aggregates appeared after prolonged
incubation (72 h) possibly indicating a common end point for
the aggregation process. The results suggest that fibrillation
and ThT fluorescence are not necessarily tightly coupled, i.e.
other aggregates than fibrillar amyloid assemblies may exhibit
increases in ThT fluorescence.
Peptide Length Determines Aggregational Propensity—The
short peptide variants A1–16 and A1–28 were studied to
investigate the influence of the peptide length on the Cu(II)-
induced aggregation, and to gain general insight into themolec-
ular mechanism of the Cu(II)-induced aggregation. The short
variants both contained the three proposed Cu(II)-binding his-
tidines and are known to bind Cu(II) in a coordination sphere
with an affinity similar to the full-length peptide (52–55). A
major difference between the two variants is that A1–28 forms
fibrils (56, 57), whereas A1–16 apparently does not (58) due to
the lack of the critical hydrophobic LVFFA sequence needed for
self-assembly (59). The spontaneous andCu(II)-induced aggre-
gation of A1–16 seemed to be very similar (Fig. 3A). Both the
apo and holo forms slowly aggregated linearly at the same rate
(Table 2) suggesting that Cu(II) does not influence the aggrega-
tion kinetics of A1–16. This was also reported previously (42),
althoughon amuch shorter time scale (2 h incubation). As seen,
50% of the peptide had aggregated after 14 days but an
increase in ThT fluorescence were not observed during this
time (data not shown). Hence, the aggregates did not contain
any -sheet structure and were most likely non-fibrillar in
nature as expected.
Cu(II)-dependent A Aggregation Pathways
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Next, the aggregation kinetics of A1–28 was monitored with
and without Cu(II). CE showed that the peak shape of A1–28
and peak appearance time were altered by the presence of
Cu(II) (Fig. 3B).Without Cu(II) the peptide peak was sharp and
symmetrical, whereas it was broader and tailing in the presence
of Cu(II). This was most likely caused by dissociation of Cu(II)
from the peptide when the sample was injected into the elec-
trophoresis buffer and electrophoresis was applied. Results
based on stopped-flow spectroscopy (27) show that the disso-
ciation rate constant of Cu(II) from the A-Cu(II) complex is
0.1 s1meaning that the complex had completely dissociated
at the time (about 9 min) of detection (60).
We found that the spontaneous aggregation of A1–28 fol-
lowed a sigmoidal curve shape that is compatible with the two-
step autocatalytic model (Fig. 3C). The rate constant for the
autocatalytic step of A1–28 aggregation is approximately an
order of magnitude smaller than for A1–40 suggesting that the
formation of aggregates is less favorable for the smaller peptide
(Table 2). Surprisingly, as with the 1–16 variant, an increase in
ThT fluorescence was not observed (data not shown) even
though the sigmoidal aggregation kinetic profile suggests that
the aggregation follows a model, which results in formation of
fibrils. This may be because the peptide concentration (40 M)
was too low to yield a discernable signal aswas reported by Shen
et al. (57) where concentrations of120M yielded an increase
in ThT fluorescence after 24 h of incubation.
When A1–28 was incubated with supra-equimolar Cu(II),
concentration changes in the aggregation profile were
observed. The two-step autocatalytic model could not describe
the data, and the decrease in soluble peptide appeared to follow
a single exponential decay (Fig. 3C). Also, as seen with the holo
forms of A1–40 there was a tendency for a faster aggregation
initially, followed by a higher stability of the soluble peptide,
although it was less evident than for A1–40. However, as seen
in Fig. 3C soluble A1–28 was still present after 11 days when
incubated with Cu(II), whereas it had fully disappeared after 6
days in the absence of Cu(II). This indicates that the Cu(II)
binding to A1–28 stabilizes ametal-peptide complex that has a
slower rate of aggregation exactly as was found for Cu-A1–40.
To sum up, the experiments with A1–16 and A1–28 showed
that other amino residues than the Cu(II) binding His residues
are of importance in the Cu(II)-induced aggregation.
Model for A Aggregation in the Absence and Presence of
Cu(II)—A mechanistic model is depicted in Fig. 4, which
describes the influence of Cu(II) on the aggregation of A1–40
including the observation that the aggregates are structurally
dynamic and undergo time-dependentmorphological transfor-
mations. The presented model shows that when Cu(II) is not
present the aggregation of A1–40 follows a mechanism that
can be described by the two-step autocatalytic model with the
formation of ThT-positive fibrils.WhenCu(II) is present it rap-
idly binds to A forming a soluble 1:1 A-Cu(II) complex. This
complex either aggregates quickly (within minutes) or remains
soluble over a long period of time (hours-days) depending on
the metal:peptide ratio, indicating the existence of multiple
aggregation pathways and/or limiting steps.
Kinetic profiles for A and Cu(II) based on numerical simu-
lations of themodel are largely compatible with the experimen-
tal data (Fig. 5 and supplemental Table S2) and with the results
of this study as well as previous reports (31, 39, 61). The ThT
profiles were not simulated because the ThT fluorescence
intensity was influenced by the addition of Cu(II). Thus differ-
FIGURE 3. Aggregation of 40M A1–16 and A1–28 showing the effect of
peptide length for the Cu(II)-induced aggregation. A, decrease in soluble
A1–16 in the absence (F, black) and presence of 200 M (f, red) Cu(II). Data
points are fitted to supplemental Equation S2. B, decrease in soluble A1–28 in
the absence (F, black) and presence of 200 M (f, red) Cu(II). Data points are
globally fitted to supplemental Equations S1 or S3. C, electropherograms at
various times (top) with and (bottom) without Cu(II) showing the disappear-
ance of soluble A1–28 due to aggregation. A marker peptide (M) is added to
the solution. The experimental conditions were the same as described in the
legend to Fig. 1.
Cu(II)-dependent A Aggregation Pathways
JULY 29, 2011•VOLUME 286•NUMBER 30 JOURNAL OF BIOLOGICAL CHEMISTRY 26959
 at D
EF Consortium
 - Danm
arks Tekniske Inform
ationscenter, on August 8, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
ent types of A-Cu(II) aggregates are likely to have different
ThT fluorescence responses, and it would not be possible to
determine the fluorescence contribution of the individual spe-
cies based on our studies. The model for the spontaneous
aggregation, i.e. the two-step autocatalytic model (supplemen-
tal Equation S1) used rate constants based on the experimental
data (Table 1). The simulated profiles justify that ourmodel and
proposed rate-limiting steps may provide kinetic profiles that
are comparable with those obtained in the study (Figs. 1 and 5).
DISCUSSION
This study shows that Cu(II) has a great influence on the
kinetics, aggregate morphology, and aggregate dynamics of
polymeric A in accordance with previous studies (5, 26, 42,
61). The metal:peptide ratio was found to be very important
in this respect, which is also supported by previous studies
(15, 49, 50). Unlike previous studies, however, this study is
based on the combined kinetic analysis of both the loss of
soluble peptide, aggregate/fibril growth, the aggregation of
TABLE 2
Rate constants for the aggregation of A1–16 and A1–28 (40M) with and without the addition of Cu(II) (200M)
The experimentswere performed at 37 °C in 20mMHEPES buffer with 100mMNaCl (pH 7.4). Values are best-fitted values S.E. n is the number of individual experiments.
For the two-phase AC model k1 is the rate constant of nucleation, and k2 is the rate constant of fibril growth. For the linear function model, k1 is the 0 order rate constant.
For the monoexponential model k1 is the rate constant for the exponential term. For more details see the supplemental materials.
System Model k1 k2
A1–16 Linear functiona (n 4)b (1.78 0.07) 105 M s1
A1–16 Cu(II) Linear functiona (n 4)b (1.97 0.01) 105 M s1
A1–28 Two-phase ACc (n 4)b (1.7 0.3) 107 s1 (3.0 0.2) 107 M1 s1
A1–28 Cu(II) Monoexponentiald (n 4)b (2.0 0.8) 107 s1
a Supplemental Equation S2.
b Global fit.
c Supplemental Equation S1.
d Supplemental Equation S3.
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P, soluble peptide (A); F, ThT fluorescence;M, soluble metal (copper).
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peptide-bound Cu(II), and the morphology of the formed
aggregates. This approach allows a more rigorous analysis of
kinetic data and enables us to probe deeper into the under-
lying Cu(II)-induced aggregation mechanisms. Most impor-
tantly, we here report for the first time that at least three
distinct Cu(II)-induced aggregation scenarios exist. The
three scenarios were all different from the sigmoid fibrilla-
tion kinetics seen for apo-A and each one was dependent
on the Cu(II):A ratio. We found that Cu(II) both promoted
and inhibited A aggregation depending on both the metal:
peptide ratio and the time of incubation as seen at supra-
stoichiometric Cu(II) concentrations. This may provide an
explanation for some of the contradicting reports in the lit-
erature on this subject. The discovery of distinct Cu(II)-de-
pendent aggregation pathways suggests that future cytotox-
icity studies need to take these aggregation mechanisms into
account.
Recently, it has been proposed that themetal-induced aggre-
gation of A proceeds via building blocks of metal-A and that
the formation of a A2-metal2 dimer is the rate-limiting step in
the aggregation mechanism (31, 44). Although such a mecha-
nism may account for some of the kinetic profiles that were
observed in this study, it is not sufficient for a complete descrip-
tion at all concentration levels. Especially intriguing is the fact
that the A1–40 samples containing equimolar concentrations
of Cu(II) behave very differently from samples at both the sub-
and supra-equimolarCu(II) concentrations.Uniquely, equimo-
lar conditions exhibit decreased initial metal-induced A1–40
aggregation and a slow constant disappearance rate of both
A1–40 and Cu(II). An explanation could be that several con-
formations of the soluble Cu-A complex exist (42, 58), and
that the conformational equilibrium of this complex is affect-
ed by the metal:peptide ratio (16, 23, 39). EPR (62–64) and
stopped-flow fluorescence experiments (27) with A and
Cu(II) confirm the co-existence of at least two different A-Cu
conformations at neutral pH. The difference, especially in the
initial part of the kinetic curve between the aggregation exper-
iments conducted at equimolar and supra-equimolar Cu(II)
concentrations, could then be a direct consequence of a confor-
mational equilibrium shift in the A-Cu(II) complex, possibly
involving the second binding site at the supra-equimolar Cu(II)
concentration, because we here found that the metal:peptide
stoichiometry in the aggregates was 1.4. This means that the
dual effect of Cu(II) on the aggregation kinetics is most likely
directly linked to the different Cu(II) coordination environ-
ments in A (31, 65).
The experiments with A1–16 and A1–28 showed that the
ability of Cu(II) to affect the aggregation kinetics is closely
related to the spontaneous aggregation mechanism. We
observed that only when the spontaneous aggregation followed
a two-step autocatalytic mechanism (A1–28 and A1–40) did
Cu(II) affect the aggregation kinetics. This suggests that Cu(II)
shifts the A aggregation pathway from a fibrillar route to a
non-fribillar route, which would also be in accordance with the
morphological results and other studies (39, 44). This effect is
most likely not solely related to theCu(II)-bindingHis residues,
because Cu(II) did not affect the aggregation of A1–16. Thus,
other factors, e.g. the chemistry of the peptide backbone or non-
specific binding to some of the amino acids as suggested for
human muscle acylphosphatase (66), could be of importance.
The schematic mechanistic model presented in Fig. 4 indi-
cates that the presence of a slow-aggregating soluble A-Cu(II)
oligomer could act as a rate-limiting step for the overall aggre-
gation process. This could be important for understanding the
A-Cu(II)-mediated neurotoxicity in Alzheimer disease as it
has been suggested that it is a soluble form of Cu(II)-A, which
exerts the Cu(II)-mediated neurotoxicity, most likely through
the generation of reactive oxygen species (14, 16, 35). Also,
observations that A-Cu(II) is only neurotoxic at Cu(II):A
ratios 1 with the 1:1 ratio being the most toxic (15, 16) is in
agreement with the stabilizing effect of equimolar Cu(II) con-
centrations on the soluble A species. Thus, compounds that
canmodulate or shift the equilibriumof theA-Cu(II) complex
to a less stable conformation or toward a non-toxic aggregated
state could be a new therapeutic strategy for treating AD. Here
it should be mentioned that a recent study showed, contrary to
the previous reports, that it is the substoichiometric Cu(II) con-
centrations that are most cytotoxic, whereas an equimolar
Cu(II) concentration does not increase A cytotoxicity, and
supra-stoichiometricCu(II) concentrations reduce cytotoxicity
(24).
We point out that the presented model, like any model, rep-
resents a simplified depiction of the possible events. Especially
important for therapeutic applications is the fact that not all
possible soluble and hence potentially toxic species are explic-
itly depicted. This is illustrated by the oligomerization pro-
cesses for A-Cu(II) (PM in supplemental Table S2) and
A-Cu2 (PMM in supplemental Table S2) resulting in oligo-
meric A-Cu(II) species (C and C1 in supplemental Table S2).
These steps are reduced to one overall (fast) step, because they
are not assumed to be rate-limiting (Fig. 4). In this respect it is
noted that the oligomerization of actin and tubulin has been
reported (67) to be on the order of 0.5–10  106 M1 s1 and
102–104 times larger than the lower limit for the rate constants
FIGURE 5. Simulation of the concentrations of soluble A andCu(II) upon
incubation. The simulated curves are based on numerical integration of the
differential equations and conditions (rate constants and concentrations)
presented in supplemental Table S2. Experimental data for CE (circles) and
ICP-MS (open squares) are superimposed on the simulated pair of curves for
each condition. Data are taken from both Fig. 1 and supplemental Fig. S1.
Concentrations for both A and Cu(II) are normalized to the starting concen-
trationofA (40M). Color code:black, noCu(II);blue, Cu(II):A0.25;purple,
Cu(II):A 1; red, Cu(II):A 5.
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for the oligomerization processes used to simulate the profiles
shown in Fig. 5.
Moreover, the presented model is based on in vitro data
obtained in a simplified system consisting only of peptides,
ions, and buffers. In vivo many factors, e.g. other proteins and
small peptides, could possibly affect the Cu2-induced aggre-
gation of A. In this connection an interesting protein is met-
allothionein-3, which has the ability to exchange Cu(II) with
Zn(II). A recent study shows that this could be an important
factor in the A-Cu(II)-mediated cytotoxicity (13). Valuable
additions to our model would be the implementation of kinetic
aggregate size (e.g. size exclusion chromatography) and struc-
tural studies (e.g. circular dichroism or NMR) to gain further
insight in the structure-function relationship of the Cu(II)-in-
duced A oligomerization and aggregation.
Finally, we note that themodel presented in Fig. 4 address the
extracellular interaction between Cu(II) and A. Studies sug-
gest that accumulation of intracellular A is also implicated in
the development of AD (68, 69) (reviewed in Ref. 70). Thus, it is
possible that intracellular Cu could also play a role in this accu-
mulation, although the oligomerization mechanism would
most likely differ from the extracellular scenario due to the
reductive intracellular environment, and the presence of cellu-
lar components. Nonetheless, the presented model provides
novel insight in the underlying Cu(II)-induced aggregation
mechanism of A, and offers an explanation for the different
aggregation scenarios observed in this study.
In addition to the implications for understanding AD it is
increasingly recognized that several other amyloidogenic pro-
teins associated with clinical important amyloidosis, e.g.2-mi-
croglobulin (dialysis-related amyloidosis) (71), prion protein
(spongiform encephalopathies) (72), and -synuclein (Parkin-
son disease) (73), may bindmetal ions with modulation of their
aggregation pathway as a consequence. Hence it is plausible
that at least some of these proteins could share identical or
similar metal-induced aggregation mechanisms and/or patho-
logical pathways (65), and that the model presented in this
study can serve as a template in the search for a unified under-
standing of mechanisms of amyloidogenicity.
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